| dbo:abstract
|
- Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
- L'énasidénib (INN, nom commercial Idhifa) est un médicament indiqué dans le traitement des leucémies aiguës myéloïdes récidivantes ou réfractaires chez les personnes présentant des mutations spécifiques du gène de l'isocitrate déshydrogénase 2 (IDH2). C'est un inhibiteur de l'IDH2. Il a été développé par Agios Pharmaceuticals et est concédé à Celgene sous licence. (fr)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEBI
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:medlinePlus
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 7403 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chebi
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:f
| |
| dbp:h
| |
| dbp:index2Label
| |
| dbp:kegg
| |
| dbp:legalAu
| |
| dbp:legalCa
| |
| dbp:legalUs
| |
| dbp:medlineplus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pdbLigand
| |
| dbp:pregnancyAu
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:stdinchi
|
- InChI=1S/C19H17F6N7O/c1-179-27-15-30-1431-1628-10-6-7-26-131925/h3-8,33H,9H2,1-2H3, (en)
|
| dbp:stdinchikey
|
- DYLUUSLLRIQKOE-UHFFFAOYSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
- L'énasidénib (INN, nom commercial Idhifa) est un médicament indiqué dans le traitement des leucémies aiguës myéloïdes récidivantes ou réfractaires chez les personnes présentant des mutations spécifiques du gène de l'isocitrate déshydrogénase 2 (IDH2). C'est un inhibiteur de l'IDH2. Il a été développé par Agios Pharmaceuticals et est concédé à Celgene sous licence. (fr)
|
| rdfs:label
|
- Enasidenib (en)
- Énasidénib (fr)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
